Corvus Pharma lost $20.3 million last quarter and spent $17.8 million on research.

Nov 5, 2026, 5:18 PM ETResultsRead the original at Benzinga

Neutral

Corvus expects its cash to fund operations into Q2 2028, supporting its ongoing studies. But research costs and losses rose, and key trial data are expected in 2027, so the report points both ways.

CRVS · Corvus Pharmaceuticals

AI read · Neutral

The AI's read

The cash gives Corvus time to keep its studies running into 2028. Its main trials remain underway, with key data expected in 2027. At the same time, research costs climbed and the quarterly loss nearly doubled from a year earlier. With key trial data still ahead, the cash runway does not settle this mixed picture.

Get alerts for CRVS

Follow Corvus Pharmaceuticals (CRVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRVS

Free on the App Store and Google Play, or on the web.